ALX 0141 for prevention of postmenopausal osteoporosis.
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2011
At a glance
- Drugs ALX 0141 (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- Sponsors Ablynx
- 16 Nov 2011 Status changed from active, no longer recruiting to completed, according to an Ablynx media release.
- 28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.
- 25 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism (EULAR-2011) (abstract OP-0198)